FOI.ICB-2526/157: Bevacizumab Gamma (Lytenava®) for Neovascular (wet) Age-related Macular Degeneration (NICE TA1022) FOI.ICB-2526/157: Bevacizumab Gamma (Lytenava®) for Neovascular (wet) Age-related Macular Degeneration (NICE TA1022) Nazwa pliku: FOI.ICB-2526_157-BEVACIZUMAB-GAMMA-FINAL-RESPONSE.PDF Typ pliku: PDF Rozmiar pliku: 289 KB Pobierz